Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bart Dolmatch

Vascular & Interventional Radiology Mountain View, CA Medical Doctor

NPI 1649233354 CMS profile 256386

701 E El Camino Real, Mountain View, CA 94040

Open in the dashboard

General payments

$1,718,639

239 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$106,385

2 holdings reported · through program year 2025

Research they led as principal investigator

$750 paid to institutions, not to them · program year 2019

Through program year 2025, Bart Dolmatch of Mountain View, CA is reported in the CMS Open Payments database as having received $1,718,639 across 239 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $750 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $106,385 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $586,591 29
2024 General $386,389 45
2023 General $315,747 36
2022 General $236,159 50
2021 General $65,797 23
2020 General $20,487 9
2019 General $107,470 47
2022 Ownership $53,193 1
2021 Ownership $53,193 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bart Dolmatch
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Bart Dolmatch were reported at $586,591. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Bart Dolmatch Vascular & Interventional Radiology median Middle half National median
2019 $107,470 $422 $125–$1,555 $163
2020 $20,487 $200 $68–$652 $114
2021 $65,797 $280 $99–$866 $132
2022 $236,159 $433 $137–$1,497 $149
2023 $315,747 $506 $152–$2,019 $160
2024 $386,389 $556 $175–$1,930 $164
2025 $586,591 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merit Medical Systems Inc $1,582,605 57 payments
  2. Bard Peripheral Vascular, Inc. $107,839 74 payments
  3. Medtronic, Inc. $11,792 32 payments
  4. Boston Scientific Corporation $5,509 18 payments
  5. Medtronic Vascular, Inc. $5,364 15 payments
  6. Penumbra, Inc. $2,629 14 payments
  7. Inari Medical, Inc. $1,618 7 payments
  8. Abbott Laboratories $185 2 payments
  9. Okami Medical, Inc. $167 1 payment
  10. Sirtex Medical Inc $147 6 payments
  11. Other $786 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $1,462,462 21 payments
  2. Consulting Fee $173,869 66 payments
  3. Honoraria $26,638 7 payments
  4. Travel and Lodging $25,835 26 payments
  5. Education $9,200 2 payments
  6. Food and Beverage $7,080 111 payments
  7. Compensation for serving as faculty or as a speaker for a medical education program $6,250 3 payments
  8. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,000 1 payment
  9. Current or prospective ownership or investment interest $2,306 1 payment
  10. Grant $2,000 1 payment
Products named General payments · program years 2019–2025
  1. Wrapsody Stent Graft $1,504,933 35 payments
  2. FLUENCY $11,517 3 payments
  3. ELLIPSYS VASCULAR ACCESS SYSTEM $7,584 8 payments
  4. CONQUEST $6,000 1 payment
  5. IN.PACT Admiral $5,364 15 payments
  6. COVERA $4,200 2 payments
  7. LUTONIX $3,200 1 payment
  8. Clinical Trial Product $3,000 3 payments
  9. WavelinQ $2,588 1 payment
  10. Indigo System $2,442 11 payments
  11. Other $14,215 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 158 billing codes

Paid by Medicare

$139,292

Medicare's payments for the services billed

Medicare patients

454

Average age 77

Services billed

1,623

240 women, 214 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Chronic kidney disease 39%
Ischemic heart disease 36%
Cancer 35%
Diabetes 33%
Atrial fibrillation 31%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record